被忽视的热带疾病诊断市场 - 全球行业规模、份额、趋势、机会和预测，按疾病、按诊断方法、按服务类型、按最终用途、按地区和竞争进行细分，2020-2030 年预测

2024 年全球被忽视的热带疾病诊断市场价值为 62 亿美元，预计在预测期内将实现令人印象深刻的成长，到 2030 年的复合年增长率为 4.09%。被忽视的热带疾病 (NTD) 是指一组主要影响世界低收入和热带或亚热带地区人口的传染病。这些疾病的特点是在边缘化和贫困社区中流行，这些社区的人们往往缺乏足够的医疗保健、清洁水、卫生设施和预防措施。被忽视的热带疾病对世界上最贫穷和最边缘化的人口影响最为严重，特别是那些居住在农村或城市贫民窟地区的人。这些社区通常缺乏基本的医疗服务。被忽视的热带疾病是由多种传染源引起的，包括细菌、病毒、寄生虫和原生动物。这些疾病的传播通常与环境因素和媒介有关，例如蚊子或苍蝇。被忽视的热带疾病倡导团体和宣传活动在提高公众和政界对这些疾病的认识方面发挥了重要作用。这为诊断和治疗工作带来了更大的支持。

主要市场驱动因素

诊断学的进步

主要市场挑战

缺乏敏感且特异的检测

主要市场趋势

注重早期检测

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球被忽视的热带疾病诊断市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依疾病分类（登革热、基孔肯雅热、狂犬病、布鲁里溃疡、雅司病、淋巴丝虫病、绦虫病/囊虫病、麦地那龙线虫病等）
  • 依诊断方法（传统、分子/现代）
  • 依服务类型（集中服务、POC 服务）
  • 依最终用途（临床实验室、医院/诊所、家庭医疗保健）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 6 章：亚太地区被忽视的热带疾病诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 7 章：欧洲被忽视的热带疾病诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 8 章：北美被忽视的热带疾病诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 9 章：南美洲被忽视的热带疾病诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲被忽视的热带疾病诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 13 章：全球被忽视的热带疾病诊断市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章： 大环境分析

第 16 章：竞争格局

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc.
• ZeptoMetrix LLC
• InBios International, Inc.
• Genome Diagnostics Pvt. Ltd.
• Omega Diagnostics Group Plc
• Coris Bioconcept
• Oscar medicare Pvt Ltd.
• DiaSys Diagnostics Systems GmbH

第 17 章：策略建议

第18章调查会社について・免责事项

Global Neglected Tropical Diseases Diagnosis Market was valued at USD 6.20 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 4.09% through 2030. Neglected Tropical Diseases (NTDs) refer to a group of infectious diseases that primarily affect populations in low-income and tropical or subtropical regions of the world. These diseases are characterized by their prevalence in marginalized and impoverished communities, often lacking access to adequate healthcare, clean water, sanitation, and preventive measures. NTDs disproportionately affect the world's poorest and most marginalized populations, particularly those living in rural or urban slum areas. These communities often lack access to basic healthcare services. NTDs are caused by a variety of infectious agents, including bacteria, viruses, parasites, and protozoa. The transmission of these diseases is often linked to environmental factors and vectors, such as mosquitoes or flies. NTD advocacy groups and awareness campaigns have played a significant role in increasing public and political awareness about these diseases. This has resulted in greater support for diagnosis and treatment efforts.

Key Market Drivers

Advancements in Diagnostics

Molecular techniques such as Polymerase Chain Reaction (PCR) and Nucleic Acid Amplification Tests (NAATs) have revolutionized NTDs diagnosis. They allow for the detection of the genetic material of pathogens with high sensitivity and specificity. Molecular diagnostics are particularly useful for diseases like Chagas disease and Leishmaniasis. For instance, according to a 2024 NCBI article, advancements in artificial intelligence are enhancing medical computer-aided diagnosis, improving accuracy, efficiency, and early disease detection for better patient outcomes.

Also, in May 2022, medical technology company Anitoa Systems launched a portable RT-PCR test for dengue virus detection, expanding its Maverick RT-PCR device line. This multiplex test detects multiple target genes linked to severe dengue, ensuring early and accurate diagnosis. Point-of-Care Testing (POCT) devices have been developed for various NTDs, enabling rapid and on-site diagnosis. These portable devices are especially valuable in remote and resource-limited settings where access to centralized laboratories is limited. Examples include rapid diagnostic tests for malaria and dengue. Serological tests detect specific antibodies produced by the immune system in response to infection. Advances in serological assays have improved their accuracy and made them more widely available for diagnosing diseases like schistosomiasis and lymphatic filariasis. Some NTDs can be diagnosed by detecting specific antigens produced by the pathogens. Antigen detection tests are valuable for diseases like African sleeping sickness and urinary schistosomiasis.

Key Market Challenges

Lack of Sensitive and Specific Tests

Many NTDs share symptoms with other diseases or have multiple stages, making accurate diagnosis difficult. When sensitive and specific tests are lacking, there's a higher risk of misdiagnosis or underdiagnosis, leading to delayed or inadequate treatment. Accurate diagnosis is essential for determining the appropriate treatment regimen. Without sensitive and specific tests, healthcare providers may resort to empirical treatment, which can result in unnecessary healthcare costs and potential drug resistance. NTDs control and elimination programs rely on accurate data to target affected populations effectively. Inaccurate diagnosis can lead to misallocation of resources, potentially slowing down progress in controlling these diseases. For tracking the prevalence and distribution of NTDs, sensitive and specific tests are crucial. Inaccurate diagnostic tools can lead to inaccurate disease surveillance data, hindering the ability to detect outbreaks or changes in disease patterns. Diagnostic tools are fundamental in research efforts related to NTDs, including drug and vaccine development. Insensitive or nonspecific tests can slow down the research process and hinder the identification of potential therapeutic targets. Patients may undergo multiple tests, sometimes invasive, to confirm an NTD diagnosis due to the lack of definitive tests. This can result in a physical and psychological burden on affected individuals. Limited healthcare resources in endemic regions should be used efficiently. Sensitive and specific tests are essential for targeting interventions to those who need them most, thereby optimizing resource allocation.

Key Market Trends

Focus on Early Detection

Early detection allows for prompt initiation of treatment, which can lead to better outcomes for patients. For many NTDs, early treatment can prevent disease progression and complications. Early diagnosis and treatment can help break the cycle of transmission of NTDs. By identifying and treating infected individuals early, there is a reduced risk of spreading the disease to others through vectors or direct contact. Some NTDs, such as lymphatic filariasis and leprosy, can cause disabling conditions if not treated early. Early detection and intervention can prevent or reduce disability and improve the quality of life for affected individuals. Early detection can be cost-effective in the long run. It reduces the need for more extensive and expensive treatments that may be required if NTDs are diagnosed at a later stage. Timely diagnosis contributes to the success of NTDs control and elimination programs. Early detection allows for more targeted and efficient interventions, which can accelerate progress toward achieving disease control goals. Some NTDs are associated with social stigma and discrimination. Early diagnosis and treatment can help individuals avoid the social consequences of living with untreated NTDs. Advances in point-of-care diagnostic technologies make it possible to diagnose NTDs quickly and accurately in resource-limited settings, enabling immediate treatment and reducing the need for follow-up visits.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories Ltd.
• Thermo Fisher Scientific Inc.
• ZeptoMetrix LLC
• InBios International, Inc.
• DiaSys Diagnostics Systems GmbH
• Genome Diagnostics Pvt. Ltd.
• Omega Diagnostics Group Plc
• Oscar Medicare Pvt Ltd.
• Coris BioConcept

Report Scope:

In this report, the Global Neglected Tropical Diseases Diagnosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neglected Tropical Diseases Diagnosis Market, By Disease:

• Dengue
• Chikungunya
• Rabies
• Buruli Ulcer
• Yaws
• Lymphatic Filariasis
• Taeniasis/Cysticercosis
• Dracunculiasis
• Others

Neglected Tropical Diseases Diagnosis Market, By Diagnostic Method:

• Conventional
• Molecular/Modern

Neglected Tropical Diseases Diagnosis Market, By Service Type:

• Centralized Service
• POC Service

Neglected Tropical Diseases Diagnosis Market, By End-Use:

• Clinical Labs
• Hospital/Clinics
• Home Healthcare

Neglected Tropical Diseases Diagnosis Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neglected Tropical Diseases Diagnosis Market.

Available Customizations:

Global Neglected Tropical Diseases Diagnosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neglected Tropical Diseases Diagnosis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease (Dengue, Chikungunya, Rabies, Buruli Ulcer, Yaws, Lymphatic Filariasis, Taeniasis/Cysticercosis, Dracunculiasis, others)
  • 5.2.2. By Diagnostic Method (Conventional, Molecular/Modern)
  • 5.2.3. By Service Type (Centralized Service, POC Service)
  • 5.2.4. By End Use (Clinical Labs, Hospital/Clinics, Home Healthcare)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Neglected Tropical Diseases Diagnosis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease
  • 6.2.2. By Diagnostic Method
  • 6.2.3. By Service Type
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease
      • 6.3.1.2.2. By Diagnostic Method
      • 6.3.1.2.3. By Service Type
      • 6.3.1.2.4. By End Use
  • 6.3.2. India Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease
      • 6.3.2.2.2. By Diagnostic Method
      • 6.3.2.2.3. By Service Type
      • 6.3.2.2.4. By End Use
  • 6.3.3. Australia Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease
      • 6.3.3.2.2. By Diagnostic Method
      • 6.3.3.2.3. By Service Type
      • 6.3.3.2.4. By End Use
  • 6.3.4. Japan Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Disease
      • 6.3.4.2.2. By Diagnostic Method
      • 6.3.4.2.3. By Service Type
      • 6.3.4.2.4. By End Use
  • 6.3.5. South Korea Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Disease
      • 6.3.5.2.2. By Diagnostic Method
      • 6.3.5.2.3. By Service Type
      • 6.3.5.2.4. By End Use

7. Europe Neglected Tropical Diseases Diagnosis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease
  • 7.2.2. By Diagnostic Method
  • 7.2.3. By Service Type
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease
      • 7.3.1.2.2. By Diagnostic Method
      • 7.3.1.2.3. By Service Type
      • 7.3.1.2.4. By End Use
  • 7.3.2. Germany Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease
      • 7.3.2.2.2. By Diagnostic Method
      • 7.3.2.2.3. By Service Type
      • 7.3.2.2.4. By End Use
  • 7.3.3. Spain Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease
      • 7.3.3.2.2. By Diagnostic Method
      • 7.3.3.2.3. By Service Type
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease
      • 7.3.4.2.2. By Diagnostic Method
      • 7.3.4.2.3. By Service Type
      • 7.3.4.2.4. By End Use
  • 7.3.5. United Kingdom Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease
      • 7.3.5.2.2. By Diagnostic Method
      • 7.3.5.2.3. By Service Type
      • 7.3.5.2.4. By End Use

8. North America Neglected Tropical Diseases Diagnosis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease
  • 8.2.2. By Diagnostic Method
  • 8.2.3. By Service Type
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Neglected Tropical Diseases Diagnosis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease
      • 8.3.1.2.2. By Diagnostic Method
      • 8.3.1.2.3. By Service Type
      • 8.3.1.2.4. By End Use
  • 8.3.2. Mexico Neglected Tropical Diseases Diagnosis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease
      • 8.3.2.2.2. By Diagnostic Method
      • 8.3.2.2.3. By Service Type
      • 8.3.2.2.4. By End Use
  • 8.3.3. Canada Neglected Tropical Diseases Diagnosis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease
      • 8.3.3.2.2. By Diagnostic Method
      • 8.3.3.2.3. By Service Type
      • 8.3.3.2.4. By End Use

9. South America Neglected Tropical Diseases Diagnosis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease
  • 9.2.2. By Diagnostic Method
  • 9.2.3. By Service Type
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Neglected Tropical Diseases Diagnosis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease
      • 9.3.1.2.2. By Diagnostic Method
      • 9.3.1.2.3. By Service Type
      • 9.3.1.2.4. By End Use
  • 9.3.2. Argentina Neglected Tropical Diseases Diagnosis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease
      • 9.3.2.2.2. By Diagnostic Method
      • 9.3.2.2.3. By Service Type
      • 9.3.2.2.4. By End Use
  • 9.3.3. Colombia Neglected Tropical Diseases Diagnosis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease
      • 9.3.3.2.2. By Diagnostic Method
      • 9.3.3.2.3. By Service Type
      • 9.3.3.2.4. By End Use

10. Middle East and Africa Neglected Tropical Diseases Diagnosis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease
  • 10.2.2. By Diagnostic Method
  • 10.2.3. By Service Type
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Neglected Tropical Diseases Diagnosis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease
      • 10.3.1.2.2. By Diagnostic Method
      • 10.3.1.2.3. By Service Type
      • 10.3.1.2.4. By End Use
  • 10.3.2. Saudi Arabia Neglected Tropical Diseases Diagnosis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease
      • 10.3.2.2.2. By Diagnostic Method
      • 10.3.2.2.3. By Service Type
      • 10.3.2.2.4. By End Use
  • 10.3.3. UAE Neglected Tropical Diseases Diagnosis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease
      • 10.3.3.2.2. By Diagnostic Method
      • 10.3.3.2.3. By Service Type
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Neglected Tropical Diseases Diagnosis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. F. Hoffmann-La Roche Ltd
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Abbott Laboratories Inc.
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Thermo Fisher Scientific Inc.
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. ZeptoMetrix LLC
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. InBios International, Inc.
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Genome Diagnostics Pvt. Ltd.
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Omega Diagnostics Group Plc
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Coris Bioconcept
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Oscar medicare Pvt Ltd.
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10. DiaSys Diagnostics Systems GmbH
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer